Buprenorphine/naloxone sublingual film

Drug Profile

Buprenorphine/naloxone sublingual film

Alternative Names: Naloxone/buprenorphine; SCH 000484; Suboxone; Suboxone film

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Reckitt Benckiser Pharmaceuticals
  • Developer Indivior; MonoSol Rx; Reckitt Benckiser Pharmaceuticals
  • Class Antidotes; Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Opioid abuse

Most Recent Events

  • 20 Nov 2017 Indivior initiates litigation against Dr Reddy's over ANDA submission for buprenorphine/naloxone sublingual film in USA
  • 25 Sep 2017 Indivior and Monosol Rx entered into a settlement agreement with Mylan for resolving patent litigation related to buprenorphine/naloxone sublingual film ANDA application by Mylan
  • 25 Sep 2017 Indivior has patent protection for Buprenorphine/naloxone sublingual film in USA, before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top